The Usefulness of Fecal Calprotectin in Differentiating between Functional and Organic Bowel Diseases: Application in Pediatric Constipation Patients

Sung Noh Hong

doi:10.4166/kjg.2013.62.5.261

Journal List > Korean J Gastroenterol > v.62(5) > 1007153

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Hong: The Usefulness of Fecal Calprotectin in Differentiating between Functional and Organic Bowel Diseases: Application in Pediatric Constipation Patients

Editorial

Korean J Gastroenterol 2013;62(5):261-262.

Published online: 4 October 2013

DOI: https://doi.org/10.4166/kjg.2013.62.5.261

The Usefulness of Fecal Calprotectin in Differentiating between Functional and Organic Bowel Diseases: Application in Pediatric Constipation Patients

Sung Noh Hong

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Correspondence to: Sung Noh Hong, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. Tel: +82-2-3410-3409, Fax: +82-2-3410-6983, E-mail: gisnhong@gmail.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Article

Role of Fecal Calprotectin in Differentiating between Hirschsprung's Disease and Functional Constipation

References

1. Lee KM. Fecal biomarkers in inflammatory bowel disease. Intest Res. 2013; 11:73–78.

2. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2007; 25:247–255.

3. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12:524–534.

4. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007; 102:803–813.

5. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011; 140:1817–1826.

6. Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001; 32:171–177.

7. Canani RB, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008; 40:547–553.

8. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001; 49:402–408.

9. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic metaanalysis. BMJ. 2010; 341:c3369.

10. Hoff G, Grotmol T, Thiis-Evensen E, Bretthauer M, Gondal G, Vatn MH. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut. 2004; 53:1329–1333.

11. Mahjoub FE, Zahedi N, Ashjai B, et al. Role of fecal calprotectin in differentiating between Hirschsprung's disease and functional constipation. Korean J Gastroenterol. 2013; 62:288–291.

12. Teitelbaum DH, Qualman SJ, Caniano DA. Hirschsprung's disease. Identification of risk factors for enterocolitis. Ann Surg. 1988; 207:240–244.

13. Wassell J, Wallage M, Brewer E. Evaluation of the Quantum Blue^Ⓡ rapid test for faecal calprotectin. Ann Clin Biochem. 2012; 49:55–58.

TOOLS

Similar articles